Regensight announces that a new research & development unit has been established in the metropolitan city of Reggio calabria and that it will be active from 1 September 2022. The laboratory, strongly desired by the co-founders, was created to stren ...
We are pleased to announce the start of the multicenter randomized clinical trial aiming at assessing theranostic-guided corneal cross-linking for treatment of keratoconus. The clinical trial is conducted at three of the major Italian Universities devo ...
We are pleased to communicate that the randomized clinical study RSKC001 has been granted by the Italian Ministry of Health according to new Medical Device Regulation (MDR) 2017/745.The scope of the study is to validate the theranostic-guided corneal cro ...
Pleased to announce the installation of C4V CHROMO4VIS at the INVISTA eyeclinic in Rome (Italy).The UV-A medical device is no available to eye surgeons who want to improve their care to young patients afflicted by keratoconus with the most advanced state ...
Very nice time spent in Genova among the Meet in Italy for Life Sciences 2021 finalists. Happy to be awarded by Innovup-Italian Innovation & Startup Ecosystem!
Regensight ha la missione di migliorare la vita ai giovani pazienti affetti da cheratocono
Regensight is pleased to announce holding ISO 13485:2016 certified quality management system
